Health economic analysis in favor of Septin9 testing presented by renowned Stanford University researcher at Digestive Disease Week 2011 Patient behavior study underway to demonstrate compliance benefit ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/molecular diagnostics Subtitle: Health economic analysis in favor [...]
Tag Archive > Dna Methylation
EANS-Adhoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 28.02.2011 Berlin, Germany, February 28, 2011 – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer [...]
EANS-News: Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing
QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Joint Ventures/Cooperation/Collaboration/New Products/Molecular diagnostics Subtitle: QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted [...]
EANS-News: Warnex Launches Colorectal Cancer Blood Testing Service in Canada Using Epigenomics’ Septin9 Biomarker
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Berlin, Germany, and Laval, QC, Canada, December 6, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company and Warnex Medical Laboratories, a division of Warnex Inc. (TSX: [...]
EANS-News: Epigenomics and Predictive Biosciences Extend Licensing Deal for Prostate Cancer Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Licensing Agreements/Company Information/Molecular diagnostics BERLIN, PHILADELPHIA, PA and LEXINGTON, MA, November 16, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel [...]
EANS-News: Epigenomics’ Licensee ARUP Reports Excellent Validation Results for Septin9 Colorectal Cancer Blood Test
Presentation at ASCO – NCI – EORTC Molecular Markers Meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Presentation at ASCO – NCI – EORTC Molecular Markers Meeting Berlin and Seattle – October 20, 2010 (euro adhoc) – Epigenomics AG’s [...]
EANS-News: Epigenomics CEO to give Corporate Update at Investor Conferences in Europe and U.S.
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Press release, Berlin, Germany, and Seattle, WA, U.S.A., September 3, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company informed, that Geert W. Nygaard, CEO Epigenomics AG, [...]
EANS-News: Epigenomics AG: Licensee ARUP Launches Septin9 Colorectal Cancer Blood Test in the United States
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics/Partnerships Press release Berlin and Seattle, July 21, 2010 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX) announced that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., has launched a laboratory-developed test [...]
EANS-Adhoc: Ad Hoc Announcement pursuant to para 15 WpHG (German Securities Trading Act) Epigenomics AG: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 20.07.2010 Berlin and Seattle, July 20, 2010 – Epigenomics AG (ISIN: DE000A0BVT96) reports that its licensee ARUP Laboratories, Salt [...]
EANS-News: Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial
Epi proLung BL Reflex Assay demonstrates outstanding technical and clinical performance in pivotal IVD performance evaluation study Novel test introduced to leading pathologists and Oncologists CE-marking and launch as IVD test expected within the next few weeks ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. [...]
EANS-News: Epigenomics AG Receives Allowance of Key Patent in the U.S.
Patent covers detection of colorectal cancer with Septin9 Biomarker ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Patents, Copyright & Trademarks/Molecular diagnostics Subtitle: Patent covers detection of colorectal cancer with Septin9 Biomarker Press release, Berlin, Germany, and Seattle, WA, USA, April 27, 2010 (euro [...]
EANS-News: Epigenomics AG Introduces New Lung Cancer Test at German Cancer Congress
New IVD test expected to be launched in Q2 2010 Test supports accurate diagnosis of lung cancer in suspicious cases Conference presentations on scientific evidence and clinical utility ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics/ Congress Subtitle: New IVD test [...]
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 11.01.2010 Berlin, January 11, 2010 – Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, informs that Quest Diagnostics [...]
EANS-News: Epigenomics AG: U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Licensing Agreements/Molecular Diagnostics Press release, Berlin, Germany, and Seattle, WA, USA, November 2, 2009 (euro adhoc) – The cancer molecular diagnostics company Epigenomics AG (Frankfurt Prime Standard: ECX) today announced that Quest Diagnostics Incorporated, Madison, [...]
EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test to ARUP Laboratories, Inc.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Licensing Agreements/Molecular diagnostics 12.08.2009 Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, today announced that it signed a non-exclusive licensing agreement [...]
